RE: Solvonis interview7 Jan 2026 15:24
Nice, very nice indeed....
Looking ahead to Q1 2026, Tennyson highlighted the milestones investors should monitor, including completion of in-vivo work, confirmation of brain activity, narrowing the candidate set, and final lead selection. He described this as βa key inflection point as the program transitions from discovery to IND enabling work.β
Beyond PTSD, Tennyson discussed broader pipeline progress across addiction and psychiatric indications.
He said 2026 could be a catalyst-rich year, with advancement of clinical programs, potential partnering discussions, and continued progress within the companyβs discovery engine.